key: cord-1012145-yyco084q
authors: Bekliz, M.; Adea, K.; Essaidi, M.; Sacks, J. A.; Escadafal, C.; Kaiser, L.; Eckerle, I.
title: Analytical comparison of nine SARS-CoV-2 antigen-detecting rapid diagnostic tests for emerging SARS-CoV-2 variants
date: 2021-06-03
journal: nan
DOI: 10.1101/2021.05.31.21258111
sha: 26450365954afa255c3a38ca0d045b2f397bc211
doc_id: 1012145
cord_uid: yyco084q

Several SARS-CoV-2 variants of concern/interest (VOC/VOI) emerged recently, with VOCs outcompeting earlier lineages on a global scale. To date, few data on routine diagnostic performance for VOC/VOIs are available. Here, we investigate the analytical performance of nine commercially available antigen-detecting rapid diagnostic tests (Ag-RDTs) for VOC B.1.1.7, B.1.351, P.1 and VOI P.2 with cultured SARS-CoV-2. Comparable or higher sensitivity was observed for VOC/VOI compared to a non-VOC/VOI early-pandemic virus.

SARS-CoV-2; COVID-19; coronavirus; rapid diagnostic test; variant of concern; variant of interest; sensitivity . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.05.31.21258111 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Several SARS-CoV-2 variants of concern/interest (VOC/VOI) emerged recently, with VOCs outcompeting earlier lineages on a global scale. To date, few data on routine diagnostic performance for VOC/VOIs are available. Here, we investigate the analytical performance of nine commercially available antigen-detecting rapid diagnostic tests (Ag-RDTs) for VOC B.1.1.7, B.1.351, P.1 and VOI P.2 with cultured SARS-CoV-2. Comparable or higher sensitivity was observed for VOC/VOI compared to a non-VOC/VOI early-pandemic virus for all Ag-RDTs.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.05.31.21258111 doi: medRxiv preprint When analyzing results normalized to PFU/mL, comparable or better performance to the earlypandemic lineage was observed for B.1.1.7, B.1.351, P.1 and P.2 for all assays (Figure) .

Overall sensitivity and specificity for individual isolates varied between Ag-RDTs, with the best-performing assay positive at dilutions as low as 2.43 Log10 PFU/mL and the lowersensitive assays positive at 4.54 Log10 PFU/mL. Consistently, the highest sensitivity was seen for P.1 and P.2. Although testing for analytical sensitivity with cultured virus cannot fully replace clinical data, our data provide reassuring results for the use of Ag-RDTs to diagnose VOCs. Phenotypic properties, such as a remarkable difference in the RNA:infectious virus ratio, could hint at production of defective viral particles. Their impact on diagnostic test performance should be further investigated. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.05.31.21258111 doi: medRxiv preprint

SARS-CoV-2 rapid antigen test: High sensitivity to detect infectious virus

Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. Lancet Microbe 2021. 3. WHO. Weekly epidemiological update on COVID-19 -11

Detection of the new SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in five SARS-CoV-2 rapid antigen tests (RATs)

Guidance SARS-CoV-2 lateral flow antigen tests: evaluation of VUI-202012/01

We thank Erik Boehm for language editing.

The authors have no conflicts of interest to declare.. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.05.31.21258111 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.05.31.21258111 doi: medRxiv preprint